Beijing Luzhu Biotechnology Co., Ltd. (Luzhu Biotechnology) issued a supplemental announcement to its 2025 Annual Report, providing two key updates:

1. Participant Cap Under 2025 Share Award Scheme • No individual may receive awards that would result in cumulative share entitlements exceeding 1% of the Company’s issued share capital within any rolling 12-month period, unless such a grant is separately approved by shareholders at a general meeting. • The limit calculation includes all shares already issued or to be issued from previous awards or options granted during the same 12-month window.

2. Clarification on Equity-Linked Agreements • The Company confirmed that, other than the 2025 Share Award Scheme, it neither entered into nor maintained any equity-linked agreements that could lead to the issuance of new shares during the reporting period ended 31 December 2025.

The Board emphasized that these clarifications do not affect any other information disclosed in the 2025 Annual Report, which remains unchanged.